Skip to main content
. Author manuscript; available in PMC: 2022 Feb 17.
Published in final edited form as: Clin Exp Hypertens. 2020 Oct 18;43(2):175–180. doi: 10.1080/10641963.2020.1836191

Figure 3: Effect of L-buthionine sulfoximine (BSO) and ML385 treatment on Nrf2 and phase II antioxidant enzymes in renal cortical homogenates.

Figure 3:

(a) two representative nuclear factor E2-related factor 2 (Nrf2) protein blots and a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) blot. lane 1, control, mice kept on tap water; lane 2, BSO, mice provided with 10 mmol/L BSO; lane 3, BSO+ML385, mice provided with both BSO and ML385.; lane 4, ML385, mice provided with 10 mg/kg body weight/day of ML385; Molecular weight (MW); (b) NAD(P)H: quinone oxidoreductase-1 (NQO-1) mRNA levels, (c) bar representing NQO-1 protein content; top: a representative NQO-1 and GAPDH blot: lane 1, control; lane 2, BSO; lane 3, BSO+ML385; lane 4, ML385 and enzymatic activity of (d) NQO-1 and (e) superoxide dismutase (SOD) in mice renal cortical homogenates.

Data are expressed as means ± SE of n=6 mice/group. *P<0.05 vs. control and #P<0.05 vs. BSO.

HHS Vulnerability Disclosure